Long-Term Outcomes of Teplizumab in Routine Clinical Care

Inclusion Criteria

• •Participants who have received at least 1 teplizumab infusion within 6 weeks prior to enrollment.
• •Participants must have a confirmed diagnosis of Stage 2 T1D according to the treating physician at the time of the first infusion of teplizumab.
• •(Note: Participants who progress to Stage 3 T1D by Week 6 will still be eligible, provided they were in Stage 2 at the time of the first teplizumab infusion.)
• •Participants (or their legal guardians, as applicable) who provide appropriate written or electronic informed consent/assent as applicable for the age of the participant and as per local regulations.